Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sarepta TherapeuticsMEX:SRPT 36 Net Current Asset Value is MXN108.64 as of Mar. 2026, which is 100% below its 10-year median of 16.66. GuruFocus rates MEX:SRPT with a GF Score™ of 36/100 and a GF Value™ of MXN2,196.07 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 941 Biotechnology companies, Sarepta Therapeutics ranks better than 68.01% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Sarepta Therapeutics's net current asset value per share for the quarter that ended in Mar. 2026 was MXN108.64.
The historical rank and industry rank for Sarepta Therapeutics's Net Current Asset Value or its related term are showing as below:
MEX:SRPT'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.92 Med: 16.66 Max: 143.33
Current: 2.93
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Sarepta Therapeutics was 143.33. The lowest was 2.92. And the median was 16.66.
MEX:SRPT's Price-to-Net-Current-Asset-Value is ranked better than 68.01% of 941
companies
in the Biotechnology industry
Industry Median: 4.98
vs MEX:SRPT: 2.93
Sarepta Therapeutics (MEX:SRPT) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Sarepta Therapeutics Net Current Asset Value Related Terms
Sarepta Therapeutics Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Sarepta Therapeutics's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sarepta Therapeutics Net Current Asset Value Chart
MEX:SRPT vs ZYME, BCAX, INVA: Net Current Asset Value Comparison
For the Biotechnology subindustry, Sarepta Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sarepta Therapeutics Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Sarepta Therapeutics's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of MXN108.64 mean?
Sarepta Therapeutics (MEX:SRPT) has a Net Current Asset Value of MXN108.64 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Sarepta Therapeutics and its competitors. This is 552% above median its historical median of 16.66. Over the past decade, Sarepta Therapeutics' Net Current Asset Value has ranged from 2.92 to 143.33. According to the industry distribution chart, Sarepta Therapeutics ranks #301 out of 941 companies in the Biotechnology industry, placing it in the top 32%.
Is Sarepta Therapeutics' Net Current Asset Value too high?
Sarepta Therapeutics' current Net Current Asset Value of MXN108.64 is 552% above median its 10-year median of 16.66. Over the past 10 years, this metric has ranged from a low of 2.92 to a high of 143.33. Based on the distribution chart, Sarepta Therapeutics ranks #301 out of 941 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sarepta Therapeutics has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Net Current Asset Value compare to ZYME and BCAX?
According to the Biotechnology industry distribution chart, Sarepta Therapeutics ranks #301 out of 941 companies for Net Current Asset Value. This puts Sarepta Therapeutics in the upper half of its industry. The industry median Net Current Asset Value is 4.98. Historically, Sarepta Therapeutics' own Net Current Asset Value has ranged from 2.92 to 143.33 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.98, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Sarepta Therapeutics and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sarepta Therapeutics's current Net Current Asset Value is MXN108.64, which is 552% above median its own 10-year median of 16.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (MEX:SRPT) is currently considered Possible Value Trap. The stock's GF Value™ is MXN2,196.07, compared to a current price of MXN294.00 — trading 86.6% below its estimated fair value. The current Net Current Asset Value is MXN108.64, which is 552% above median its 10-year median of 16.66. Sarepta Therapeutics' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Sarepta Therapeutics (MEX:SRPT), the current Net Current Asset Value is MXN108.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sarepta Therapeutics (MEX:SRPT) Overvalued in 2026?
Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued.
The current stock price of MXN294.00 is trading 86.6% below its estimated GF Value™ of MXN2,196.07.
GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.
Key valuation signals for MEX:SRPT:
Net Current Asset Value: MXN108.64 (552% above median its 10-year median of 16.66)
GF Value™: MXN2,196.07 vs. price of MXN294.00 (86.6% below fair value)
No single metric tells the full story. See the MEX:SRPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
36GF Score
Get the complete analysis for MEX:SRPT
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SRPT has been successfully added to your 
